FDA orders clinical hold on Targeted Genetics trial

Share this content:
The FDA has ordered a clinical hold on a Targeted Genetics clinical trial involving tgAAC94, an investigational therapy indicated for treating inflammatory arthritis. The hold came after one subject experienced a serious adverse event, but the company says there is insufficient information to draw conclusions as to the cause.

Share this content:
Scroll down to see the next article